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Materials and Methods: 
Synthesis of antibody-PEG conjugates: 
Cetuximab, rituximab, panitumumab, and trastuzumab were obtained from Dr. Yun Yen at the 
City of Hope. Antibody-PEG-OPSS conjugates were prepared by reacting amine groups of 
antibodies with NHS-PEG-OPSS (5kDa, Nanocs) at a 5:1 PEG to antibody ratio in 0.1 M 
phosphate buffer, pH 7.4. The conjugates were purified by high performance liquid 
chromatography (HPLC) using 0.1 M phosphate buffered saline (PBS), pH 7.4, as the elution 
buffer. Collected fractions were analyzed by matrix assisted laser desorption ionization-time of 
flight mass spectrometry (MALDI-TOF-MS).  
 
Synthesis of antibody-functionalized gold nanoparticles: 
50 nm gold nanoparticles (AuNPs) (Ted Pella) were surface functionalized with mPEG-SH (5 
kDa, Nanocs) and antibody-PEG-OPSS conjugates by mixing 50:10:1 molar ratios of 
Au:mPEG:antibody-PEG in deionized water. AuNPs were stirred at room temperature for 2 
hours. Surface functionalized AuNPs were centrifuged at 14,000 g for 10 minutes, the 
supernatant was removed, and AuNPs were washed with deionized water three times. The 
purified nanoparticles were re-suspended in deionized water or buffer solution for further 
characterization. The concentration of antibody-functionalized AuNPs was determined by 
nanoparticle tracking analysis (NTA) using a Nanosight NS500 system.  
 
Physiochemical Characterization of AuNPs: 
mPEG-AuNPs and antibody functionalized AuNPs were pelleted and were re-suspended in 
saline and deionized water. The hydrodynamic diameter and zeta potential (ζ) of mPEG-AuNPs 
and antibody functionalized AuNPs were measured using ZetaPALS (Brookhaven Instruments 
Corporation). Hydrodynamic diameter was also measured by nanoparticle tracking analysis 
(NTA) using a Nanosight NS500 system.  
 
Quantification of Antibodies per Particle: 
Fluorescent Labeling of Antibody-PEG conjugates: Dylight-650 (Pierce) labeled fluorescent 
antibody-PEG conjugates were prepared according to the manufacturer’s protocol. Antibody 
coated gold nanoparticles were synthesized using the experimental conditions described above. 
The amount of antibody in the supernatant of AuNPs was estimated by measuring the 
fluorescence of the labeled antibody using an Infinite M200 microplate reader (Tecan). The 
fluorescence of the antibody in the supernatant was subtracted from the original fluorescence 
values measured in the feed amount of antibody per sample. 
Ortho-Phthaldehyde Assay (OPA): 
Antibody-PEG conjugates bearing a base labile linker, (Bis[2-
(succinimidooxycarbonyloxy)ethyl]sulfone) (BSCOES), were prepared by mixing 
antibody:NH2-PEG-SH:BSCOES at molar ratios of 1:10:25, respectively, in 0.1 M PBS, pH 7.4. 
The conjugates were purified by HPLC. Antibody-functionalized gold nanoparticles were 
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prepared, as described above. The purified antibody-functionalized AuNPs were dispersed in 8 
mM boric acid buffer (pH 10.8) containing 3.5% Birj-35 and were incubated at 37°C overnight. 
The supernatant was collected and was reacted with 0.06M OPA in the presence of 0.025M 2-
mercaptoethanol, and fluorescence was measured using an excitation λ=340 nm and an emission 
λ=450 nm using an Infinite M200 microplate reader (Tecan). The amount of antibody on the 
AuNP surface was determined, using a calibration curve of antibody-PEG conjugates. 
 
Cell Line:  
H1975 (ATCC) was cultured in RPMI-1640 media (ATCC) containing 10% fetal bovine serum 
(FBS) in a humidified atmosphere at 37°C with 5% CO2.  
 
Cell Viability Assay: 
H1975 cells were seeded at 5,000 cells per well in 96-well plates and were treated with 
antibodies and antibody-functionalized gold nanoparticles for 72 hours. H1975 cell viability was 
evaluated using the MTS assay (Promega).  
 
In vitro Antibody Dependent Cell Cytotoxicity (ADCC) assay:  
The H1975 cell line was unable to provide satisfactory cell lysis results even with the cetuximab 
antibody alone using NKL-cells (DFCI, Boston MA), an immortalized NK cell line, and the 
lactate dehydrogenase (LDH) assay to measure ADCC in vitro. Therefore, another model using 
the BT474M1 cell line and trastuzumab to see whether ADCC occurs with the antibody, 
antibody-PEG conjugates, and antibody-functionalized AuNPs was developed. In addition to the 
Fab fragment of trastuzumab, which does not have the Fc region to which NK cells bind, 
rituximab was used as a negative control. 
Trastuzumab-Fab Synthesis:  
Trastuzumab IgG was incubated with a papain-modified agarose gel slurry (Pierce) at 37°C for 8 
hours. The enzyme to substrate ratio was 1:160 weight/weight. The digested IgG was neutralized, 
and free IgG and Fc segments were removed using a protein A column. The purified Fab was 
analyzed using sodium dodecyl sulfate poly acrylamide gel electrophoresis (SDS PAGE). 
Cell Lines: 
NKL-cells (DFCI, Boston MA) were cultured in the presence of IL-2 (Peprotech) and 10% heat 
inactivated FBS (Invitrogen). BT474M1 cells (UCSF) were maintained in RPMI-1640 media 
(Invitrogen) containing 10% ultra-low IgG FBS (Invitrogen) in humidified chambers at 37°C 
with 5% CO2. The cells were sub-cultured twice a week and were seeded in 96-well tissue 
culture plates.  
ADCC Assay: 
The cells were treated with varying concentrations of antibodies (10-0.001 µM), Fab, antibody-
PEG conjugates, and antibody-conjugated gold nanoparticles at a 10:1 ratio of NKL to 
BT474M1 cells. ADCC was evaluated 3 hours post-treatment using a lactate dehydrogenase 
(LDH) (Roche) assay according to the manufacturer’s protocol.  
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Because the same chemistry was used for antibody-PEG coupling and AuNP synthesis, the same 
phenomenon observed with trastuzumab and trastuzumab-AuNPs on the BT474M1 cell line 
should hold true for cetuximab and cetuximab-AuNPs on the H1975 cell line. 
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Xenograft Experiments: 
All mouse experiments were approved by the California Institute of Technology Institutional 
Animal Care and Use Committee. 1x10
7
 H1975 cells, suspended in 0.2 mL of serum-free RPMI-
1640 media, were injected subcutaneously into the left rear flank of each 8-week old athymic 
NCr nude mouse (Taconic Biosciences, Inc). Xenograft tumor size was monitored daily or every 
other day using electronic calipers starting 7 days post-implantation. Tumor volume was 
calculated using the equation V = W
2
 x L / 2, where W is the shortest tumor dimension and L is 
the longest tumor dimension. When tumors reached 200 mm
3
, mice were divided into groups of 
7 mice and treated via tail vein IV injection with either saline, cetuximab, or panitumumab at a 
dose of 9.34 mg/kg, or saline, cetuximab-AuNP, panitumumab-AuNP, rituximab-AuNP, or 
mPEG-AuNP at a dose of 2.25 x 10
12 
nanoparticles/25 g mouse, which corresponds to 0.4mg/kg 
of antibody per mouse. Treatment was repeated 3 times, for a total of 4 doses over 2 weeks. Mice 
were followed until tumors reached 1500 mm
3
 or for 2 months.  
 
Immunohistochemistry (IHC):  
Mice were euthanized by CO2 asphyxiation 24 hours post 2nd injection. Tumors were embedded 
in Tissue-Tek optimal cutting temperature compound (Sakura) and were frozen at -80
o
C. Tissue 
blocks were sectioned (14 µm), and were lightly fixed in 10% buffered formalin for 15 minutes. 
IHC analysis was performed for immune cell detection in tumor sections. CD45 (BD 
Biosciences), and CD11b (Biolegend) antibodies were used at 1:100 dilutions. Tissues were 
imaged using a Zeiss LSM 510 META confocal laser scanning microscope (CLSM). Gold 
nanoparticles were visualized in tissue sections using a silver enhancement kit (Ted Pella) and 
imaged with an Olympus IX50 light microscope. 
 
Sample # of Antibodies by Fluorescent 
labeling 
# of Antibodies by OPA assay 
Cetuximab-AuNPs 21±7 16±4 
Panitumumab-AuNPs 22±4 18±6 
Rituximab-AuNPs 17±3  
Table S1: Quantification of antibodies on AuNPs surface using two different methods. 
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Figure S1:  Cell viabilities of H1975 cells 72 hours post-incubation with antibodies (top) and 
antibody-functionalized AuNPs (bottom), as determined by MTS assay. Results reported in 
terms of average absorbance compared to untreated cells, with error bars denoting the standard 
error of 5 replicates. 
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Figure S2: ADCC in the BT474M1 cell line occurs with trastuzumab and trastuzumab-PEG but 
not trastuzumab-Fab or rituximab (top); and with trastuzumab AuNPs but not rituximab- or 
mPEG-AuNPs (bottom) as determined by the LDH assay. 
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Figure S3: Silver enhancement of gold nanoparticles in frozen tissue sections of tumor (pg. S7), 
liver (pg. S8), spleen (pg. S9), and kidney (pg. S10). The black patches denoted by the white 
arrows indicate the presence of gold nanoparticles in the tissue sections, which are absent from 
tissues of saline-treated mice. 
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Figure S4: CD11b staining of NK cells in tumor tissues. No difference in NK cells present in the 
tumors can be seen between the various treatment groups.  
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Figure S5: CD45 staining of frozen tumor sections as an indication of total immune cell 
infiltration present in tumors. Antibody (pg. S12) and antibody-functionalized gold nanoparticle 
(pg. S13) treated mice are shown. No difference can be seen between the various treatment 
groups. 
 
 
 
 
 
